Developer docs
API playgroundTry for free, no card

Search company profiles

KOA BIOTECH BAY

Full company profile

uuid0026ahe

Namestring
KOA BIOTECH BAY
Legal namestring
KOA BIOTECH BAY CO., LTD.
Websiteurl
biotechbay.jp
Company typeenum
Private
Founded yearint
2002
Descriptiontext

KOA BIOTECH BAY CO., LTD. (コーアバイオテックベイ株式会社) is a Japan-based pharmaceutical manufacturer founded in July 2002 and headquartered in Kohoku-ku, Yokohama. The company develops, manufactures, and sells generic (post-patent) prescription pharmaceuticals across multiple therapeutic categories — including cardiovascular (Amlodipine), anti-herpes virus (Famciclovir), osteoporosis (Minodronic acid, Zoledronic acid), ophthalmology (Latanoprost), antibiotics (Levofloxacin), and amino-acid/metabolic agents (Levocarnitine) — alongside contract manufacturing and packaging services for other pharmaceutical companies. Following the July 1, 2022 absorption merger with group company KOA Pharmaceutical Co., Ltd., the portfolio was extended to include OTC pharmaceuticals (NSAIDs, steroid ointments) and health food products, some based on traditional Japanese herbal formulas (Kampo).

The company holds First-class and Second-class manufacturing/marketing authorizations plus a general pharmaceutical manufacturing license, and operates under international GMP-compliant quality systems. Products reach end-users through Japan's pharmaceutical wholesale distribution network to hospitals, clinics, and pharmacies for the prescription portfolio, and through retail channels for the OTC and health food portfolio. Marketing to healthcare professionals is conducted via medical-representative (MR) field activities and dedicated information channels.

KOA Biotech Bay is a privately held subsidiary of KOA SHOJI HOLDINGS CO., LTD., part of a diversified Japanese trading group. Capital is stated at 10 million yen, the management team is lean (President Kazunari Fukunaga plus two Directors and one Auditor), and the operating geography is exclusively Japan. Revenue, headcount, and external funding are not publicly disclosed. The company describes its strategic mission as contributing to stable supply of generic medicines and reducing patient healthcare burden in Japan's super-aging society.

Short descriptiontext

KOA BIOTECH BAY is a Japan-based, privately held pharmaceutical manufacturer that develops, produces, and sells generic prescription drugs plus OTC and health food products, serving hospitals, pharmacies, and consumers exclusively through Japanese distribution channels.

Operating statusenum
Operating
Ownership categoryenum
akta.pro rankint
HeadquartersYokohama, Japan
HQ citystring
Yokohama
HQ countrystring
Japan
HQ regionstring
Asia
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
generic pharmaceuticals, OTC medicines, contract manufacturing, pharmaceutical packaging, health supplements
Industry2 codes
PRIMARYHLAIAAAH
Respiratory & Allergy Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAL
Ophthalmology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Generic Pharmaceuticals
No data
Revenue model3 records
1Generic pharmaceutical manufacturing and sales
TypeOne Time License
Description

Development, manufacturing, and sales of generic (post-market) pharmaceutical products, including tablet, injection, and ophthalmic formulations.

biotechbay.jp
2Contract manufacturing and packaging
TypeProfessional Services
Description

Pharmaceutical manufacturing (packaging) commissioned by other pharmaceutical companies.

biotechbay.jp
3OTC pharmaceuticals and health food sales
TypeHardware Sales
Description

Over-the-counter (non-prescription) pharmaceuticals and health food products sold directly to consumers, added following the July 2022 merger with KOA Pharma Co., Ltd.

biotechbay.jp
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Supply Chain, Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

KOA BIOTECH BAY develops, manufactures, and sells generic (post-patent) prescription pharmaceuticals in tablet, injection, and ophthalmic formulations covering therapeutic areas such as cardiovascular, anti-herpes virus, osteoporosis, ophthalmology, and anti-infectives. The company also provides contract pharmaceutical manufacturing and packaging services to other pharmaceutical firms and, following the July 2022 merger with KOA Pharmaceutical, distributes OTC medicines and health foods directly to consumers.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

KOA BIOTECH BAY CO., LTD. is a Japanese pharmaceutical company specializing in generic drugs, OTC medicines, and health products. The company operates as a contract manufacturer and seller of ethical pharmaceutical products, offering a portfolio of generic medications (including anti-herpes virus agents, calcium channel blockers, bisphosphonates, antibiotics, and eye drops) alongside OTC pharmaceuticals (NSAIDs, steroid ointments, and traditional Japanese herbal medicines) and nutritional health supplements. The company absorbed KOA Pharmaceutical Co., Ltd. in July 2022, expanding from generic drugs to include OTC medicines and health foods.

Product and service15 records
1Famciclovir Tablets 250mg "YD" (ファムシクロビル錠250mg「YD」)
CategoryGeneric prescription drug
Description

Anti-herpes virus agent generic drug for treating herpes simplex and varicella-zoster virus infections, supplied to medical institutions and pharmacies.

2Amlodipine Tablets "TYK" (アムロジピン錠「TYK」)
CategoryGeneric prescription drug
Description

Generic calcium channel blocker tablets for treatment of hypertension and angina, supplied to medical institutions and pharmacies.

3Minodronic Acid Tablets "Mikasa" (ミノドロン酸錠「三笠」)
CategoryGeneric prescription drug
Description

Generic bisphosphonate tablets for treatment of osteoporosis, supplied to medical institutions and pharmacies.

4Levofolinate IV Infusion "BT" (レボホリナート点滴静注用「BT」)
CategoryGeneric prescription drug
Description

Generic folinic acid IV formulation used as an antidote for methotrexate and in combination chemotherapy, supplied to medical institutions.

5Latanoprost Eye Drops "AA" (ラタノプロスト点眼液「AA」)
CategoryGeneric prescription drug
Description

Generic prostaglandin analog eye drops for glaucoma and ocular hypertension treatment, supplied to medical institutions and pharmacies.

6Zoledronic Acid IV Infusion Bag "Yakult" (ゾレドロン酸点滴静注バッグ「ヤクルト」)
CategoryGeneric prescription drug
Description

Generic bisphosphonate IV infusion for hypercalcemia of malignancy and bone metastases treatment, supplied to medical institutions.

7Levocarnitine Chloride Tablets "YD" (レボカルニチン塩化物錠「YD」)
CategoryGeneric prescription drug
Description

Generic carnitine supplement tablets for carnitine deficiency treatment, supplied to medical institutions and pharmacies.

8Levofloxacin Tablets "BT" (レボフロキサシン錠「BT」)
CategoryGeneric prescription drug
Description

Generic quinolone antibiotic tablets for various bacterial infections, supplied to medical institutions and pharmacies.

9Nippon Clean FC (ニッポークリーンFC)
CategoryOTC medicine
Description

Class 3 quasi-drug OTC supplement combining Vitamin B2, B6, and C for skin conditions, acne, and inflammation relief.

10Loxoprofen Tablets "GX" (ロキソプロフェン錠「GX」)
11Dermapearl Ointment (デルマパール軟膏)
12Traditional Japanese Herbal Medicine Portfolio (陀羅尼助丸, 五苓散, 当帰芍薬散, 桂枝茯苓丸, 芍薬甘草湯, 半夏厚朴湯, 桔梗湯)
13Poliguro A (ポリグロンa)
14Buraseru M2Z Plus (ブラセルM2Zプラス)
15Pharmaceutical Contract Manufacturing and Packaging Service
CategoryContract manufacturing services
Description

Pharmaceutical manufacturing (packaging) services commissioned by other pharmaceutical companies, leveraging the company's specialized packaging capabilities.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-07-01
Description

KOA Pharma Co., Ltd. was absorbed through a merger on July 1, 2022. This merger expanded KOA Biotech Bay's portfolio from solely generic pharmaceuticals to include OTC drugs and health foods, significantly broadening the company's product offerings and market reach.

2Mitsubishi UFJ Bank Musashi-Kosugi Branch (三菱UFJ銀行 武蔵小杉支店)
Strategic tierMinorTypeOthers
Description

Primary banking partner for the company.

biotechbay.jp
Strategic tierCoreTypeOthers
Description

Parent/holding company. Related group companies include KOA Shōji Co., Ltd. and KOA Isei Co., Ltd.

Strategic tierMinorTypeOthers
Description

Related group company.

5KOA Isei Co., Ltd. (コーアイセイ株式会社)
Strategic tierMinorTypeOthers
Description

Related group company.

biotechbay.jp
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Market position
Weaknesses1 record

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

KOA BIOTECH BAY

Generic Pharmaceuticalsbiotechbay.jp

KOA BIOTECH BAY is a Japan-based, privately held pharmaceutical manufacturer that develops, produces, and sells generic prescription drugs plus OTC and health food products, serving hospitals, pharmacies, and consumers exclusively through Japanese distribution channels.

What KOA BIOTECH BAY does

KOA BIOTECH BAY CO., LTD. (コーアバイオテックベイ株式会社) is a Japan-based pharmaceutical manufacturer founded in July 2002 and headquartered in Kohoku-ku, Yokohama. The company develops, manufactures, and sells generic (post-patent) prescription pharmaceuticals across multiple therapeutic categories — including cardiovascular (Amlodipine), anti-herpes virus (Famciclovir), osteoporosis (Minodronic acid, Zoledronic acid), ophthalmology (Latanoprost), antibiotics (Levofloxacin), and amino-acid/metabolic agents (Levocarnitine) — alongside contract manufacturing and packaging services for other pharmaceutical companies. Following the July 1, 2022 absorption merger with group company KOA Pharmaceutical Co., Ltd., the portfolio was extended to include OTC pharmaceuticals (NSAIDs, steroid ointments) and health food products, some based on traditional Japanese herbal formulas (Kampo).

The company holds First-class and Second-class manufacturing/marketing authorizations plus a general pharmaceutical manufacturing license, and operates under international GMP-compliant quality systems. Products reach end-users through Japan's pharmaceutical wholesale distribution network to hospitals, clinics, and pharmacies for the prescription portfolio, and through retail channels for the OTC and health food portfolio. Marketing to healthcare professionals is conducted via medical-representative (MR) field activities and dedicated information channels.

KOA Biotech Bay is a privately held subsidiary of KOA SHOJI HOLDINGS CO., LTD., part of a diversified Japanese trading group. Capital is stated at 10 million yen, the management team is lean (President Kazunari Fukunaga plus two Directors and one Auditor), and the operating geography is exclusively Japan. Revenue, headcount, and external funding are not publicly disclosed. The company describes its strategic mission as contributing to stable supply of generic medicines and reducing patient healthcare burden in Japan's super-aging society.

KOA BIOTECH BAY firmographics

Firmographics
Name
KOA BIOTECH BAY
Legal name
KOA BIOTECH BAY CO., LTD.
Website
https://biotechbay.jp
Company type
Private
Founded year
2002
Operating status
Operating
Short description
KOA BIOTECH BAY is a Japan-based, privately held pharmaceutical manufacturer that develops, produces, and sells generic prescription drugs plus OTC and health food products, serving hospitals, pharmacies, and consumers exclusively through Japanese distribution channels.
Ownership category
akta.pro rank

KOA BIOTECH BAY industry classification

Industry
Product category
Generic Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAH
Respiratory & Allergy Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAL
Ophthalmology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Generic pharmaceuticals
  • OTC medicines
  • Contract manufacturing
  • Pharmaceutical packaging
  • Health supplements

Where KOA BIOTECH BAY is headquartered

Location

Headquarters

HQ city
Yokohama
HQ country
Japan
HQ region
Asia

Offices1 record

Markets served

KOA BIOTECH BAY business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

  1. Generic pharmaceutical manufacturing and sales: Development, manufacturing, and sales of generic (post-market) pharmaceutical products, including tablet, injection, and ophthalmic formulations.
  2. Contract manufacturing and packaging: Pharmaceutical manufacturing (packaging) commissioned by other pharmaceutical companies.
  3. OTC pharmaceuticals and health food sales: Over-the-counter (non-prescription) pharmaceuticals and health food products sold directly to consumers, added following the July 2022 merger with KOA Pharma Co., Ltd.

Distribution channels1 record

Marketing channels1 record

KOA BIOTECH BAY product offering

Product offering

Core offering

KOA BIOTECH BAY develops, manufactures, and sells generic (post-patent) prescription pharmaceuticals in tablet, injection, and ophthalmic formulations covering therapeutic areas such as cardiovascular, anti-herpes virus, osteoporosis, ophthalmology, and anti-infectives. The company also provides contract pharmaceutical manufacturing and packaging services to other pharmaceutical firms and, following the July 2022 merger with KOA Pharmaceutical, distributes OTC medicines and health foods directly to consumers.

Product overview

KOA BIOTECH BAY CO., LTD. is a Japanese pharmaceutical company specializing in generic drugs, OTC medicines, and health products. The company operates as a contract manufacturer and seller of ethical pharmaceutical products, offering a portfolio of generic medications (including anti-herpes virus agents, calcium channel blockers, bisphosphonates, antibiotics, and eye drops) alongside OTC pharmaceuticals (NSAIDs, steroid ointments, and traditional Japanese herbal medicines) and nutritional health supplements. The company absorbed KOA Pharmaceutical Co., Ltd. in July 2022, expanding from generic drugs to include OTC medicines and health foods.

Differentiator

Problem solved

Functional benefit

Products and services

  • Famciclovir Tablets 250mg "YD" (ファムシクロビル錠250mg「YD」) Anti-herpes virus agent generic drug for treating herpes simplex and varicella-zoster virus infections, supplied to medical institutions and pharmacies.
  • Amlodipine Tablets "TYK" (アムロジピン錠「TYK」) Generic calcium channel blocker tablets for treatment of hypertension and angina, supplied to medical institutions and pharmacies.
  • Minodronic Acid Tablets "Mikasa" (ミノドロン酸錠「三笠」) Generic bisphosphonate tablets for treatment of osteoporosis, supplied to medical institutions and pharmacies.
  • Levofolinate IV Infusion "BT" (レボホリナート点滴静注用「BT」) Generic folinic acid IV formulation used as an antidote for methotrexate and in combination chemotherapy, supplied to medical institutions.
  • Latanoprost Eye Drops "AA" (ラタノプロスト点眼液「AA」) Generic prostaglandin analog eye drops for glaucoma and ocular hypertension treatment, supplied to medical institutions and pharmacies.
  • Zoledronic Acid IV Infusion Bag "Yakult" (ゾレドロン酸点滴静注バッグ「ヤクルト」) Generic bisphosphonate IV infusion for hypercalcemia of malignancy and bone metastases treatment, supplied to medical institutions.
  • Levocarnitine Chloride Tablets "YD" (レボカルニチン塩化物錠「YD」) Generic carnitine supplement tablets for carnitine deficiency treatment, supplied to medical institutions and pharmacies.
  • Levofloxacin Tablets "BT" (レボフロキサシン錠「BT」) Generic quinolone antibiotic tablets for various bacterial infections, supplied to medical institutions and pharmacies.
  • Nippon Clean FC (ニッポークリーンFC) Class 3 quasi-drug OTC supplement combining Vitamin B2, B6, and C for skin conditions, acne, and inflammation relief.
  • Loxoprofen Tablets "GX" (ロキソプロフェン錠「GX」)
  • Dermapearl Ointment (デルマパール軟膏)
  • Traditional Japanese Herbal Medicine Portfolio (陀羅尼助丸, 五苓散, 当帰芍薬散, 桂枝茯苓丸, 芍薬甘草湯, 半夏厚朴湯, 桔梗湯)
  • Poliguro A (ポリグロンa)
  • Buraseru M2Z Plus (ブラセルM2Zプラス)
  • Pharmaceutical Contract Manufacturing and Packaging Service Pharmaceutical manufacturing (packaging) services commissioned by other pharmaceutical companies, leveraging the company's specialized packaging capabilities.

Companies that use KOA BIOTECH BAY

Customer profile

Segments2 records

Ideal customer profiles2 records

KOA BIOTECH BAY technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

KOA BIOTECH BAY partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and minor.

Scale indicators1 record

Recent moves6 records

Expansion highlights4 records

KOA BIOTECH BAY competitors and assessment

Company assessment

Market position

Weaknesses1 record

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

KOA BIOTECH BAY compliance and trust

Trust signal

Compliance1 record

KOA BIOTECH BAY financial estimates

Financial estimate

Revenue estimate

Valuation estimate

KOA BIOTECH BAY leadership team

Management profile

Number of profiles

Profiles4 records

KOA BIOTECH BAY funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

KOA BIOTECH BAY M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about KOA BIOTECH BAY

What does KOA BIOTECH BAY do?

KOA BIOTECH BAY develops, manufactures, and sells generic (post-patent) prescription pharmaceuticals in tablet, injection, and ophthalmic formulations covering therapeutic areas such as cardiovascular, anti-herpes virus, osteoporosis, ophthalmology, and anti-infectives. The company also provides contract pharmaceutical manufacturing and packaging services to other pharmaceutical firms and, following the July 2022 merger with KOA Pharmaceutical, distributes OTC medicines and health foods directly to consumers.

Is KOA BIOTECH BAY a public or private company?

KOA BIOTECH BAY is a private company. It is classified as corporate owned and is currently operating.

When was KOA BIOTECH BAY founded?

KOA BIOTECH BAY was founded in 2002.

Where is KOA BIOTECH BAY based?

KOA BIOTECH BAY is headquartered in Yokohama, Japan, in the Asia region.

How does KOA BIOTECH BAY make money?

Three revenue lines are on record. Generic pharmaceutical manufacturing and sales are the primary driver. The others are contract manufacturing and packaging and OTC pharmaceuticals and health food sales.

Does KOA BIOTECH BAY have an API?

No public API is recorded for KOA BIOTECH BAY.

What industry is KOA BIOTECH BAY in?

KOA BIOTECH BAY's product category is Generic Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAH, Respiratory & Allergy Pharmaceuticals, with a secondary code of HLAIAAAL, Ophthalmology Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals